// App-Quantinova.ai

Abstract 8895 : Design of Phase IV, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Trial Evaluating Sodium Zirconium Cyclosilicate for the Management of Hyperkalemia in Patients With Symptomatic Heart Failure With Reduced Ejection Fraction (REALIZE-K Trial)

Researchers

Presenter

  • Mikhail Kosiborod

Principal Investigators

  • David Cherney

  • Akshay S Desai

  • Mark Petrie

  • Jeffrey Testani

  • Subodh Verma

  • Ayman Al-Shurbaji

  • James M Eudicone

  • Donna Zarzuela

Medical Centers

  • Section of Cardiovascular Medicine, Yale Univ, Guilford, CT

  • AstraZeneca, Gothenburg, Sweden

  • AstraZeneca, Gaithersburg, MD

  • Institute of Cardiovascular and Med Sciences, Univ of Glasgow, and Golden Jubilee National Hosp and Glasgow Royal Infirmary, Glasgow, United Kingdom

  • Univ Health Network and Mount Sinai Hosps and Univ of Toronto, Toronto, Canada

  • AstraZeneca, Wilmington, DE

  • Institute of Unity Health Toronto and Univ of Toronto, Toronto, Canada

  • Saint Lukes Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MO, United States

Locations

  • United States

  • Sweden

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Heart failure with reduced ejection fraction

  • Heart muscle disease

  • Congestive heart failure

  • Hyperkalemia

Biomarkers

  • N/A

Drug/Treatment

  • Sodium zirconium cyclosilicate

  • Spironolactone

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Prospective

  • Controlled

Phase

  • IV

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved